Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fuji Pharma Co., Ltd. ( (JP:4554) ) has issued an update.
Fuji Pharma Co., Ltd. has resolved to acquire and cancel all remaining stock acquisition rights from its 1st Series, originally issued to fund growth in women’s healthcare and biosimilars. This move is aimed at avoiding future dilution and will have a negligible impact on the company’s current fiscal year results, while decreasing dilutive shares by 9.8%.
More about Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. operates in the pharmaceutical industry, focusing on women’s healthcare and biosimilars. The company is engaged in research and development to bring new drugs and biosimilars to market.
Average Trading Volume: 52,034
Technical Sentiment Signal: Hold
Current Market Cap: Yen32.57B
Find detailed analytics on 4554 stock on TipRanks’ Stock Analysis page.